MU-MA402C

N/A

Report date: 2024/07/17 16:06:18

Base Information

Drug NameMU-MA402C

Drug Alias NameMU-MA402C

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsMelanoma-associated antigen 4 modulators

TargetsMelanoma-associated antigen 4

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesMie University

China Registration ClassN/A

Develop Information

Active CompaniesMie University

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A